SEOM clinical guidelines for the treatment of advanced colorectal cancer-Reference-Cited by-同舟云学术

SEOM clinical guidelines for the treatment of advanced colorectal cancer

Published:2010-11 Issue:11 Volume:12 Page:729-734
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

García-Carbonero Rocío,Gómez España M. Auxiliadora,Casado Sáenz Enrique,Alonso Orduña Vicente,Cervantes Ruipérez Andrés,Gallego Plazas Javier,García Alfonso Pilar,Juez Martel Ignacio,González Flores Encarnación,Lomas Garrido María,Isla Casado Dolores

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-010-0587-4.pdf

Reference26 articles.

1. Greene F, Page D, Fleming I et al (2002) AJCC cancer staging manual. Springer Verlag, New York

2. Van Cutsem E, Nordlinger B, Adam R et al (2006) Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 42:2212–2221

3. Choti MA, Sitzmann JV, Tiburi MF et al (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766

4. Charnsangavej C, Clary B, Fong Y et al (2006) Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 13:1261–1268

5. Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 39:818–827

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population-based universal screening for CRC: Secondary prevention;Foundations of Colorectal Cancer;2022

2. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer;BMC Cancer;2014-09-07

3. Estudio de minimización de costes de panitumumab frente a cetuximab en combinación con quimioterapia en primera línea y segunda línea en el cáncer colorrectal metastásico KRAS nativo en España;PharmacoEconomics Spanish Research Articles;2013-11-23

4. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer;Journal of Oncology Pharmacy Practice;2013-10-31

5. Análisis de patrones de tratamiento y coste farmacológico en pacientes con cáncer colorrectal metastásico en un hospital general;PharmacoEconomics Spanish Research Articles;2013-05-17